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Influence of Body Mass Index and Antibiotic
Dose on the Risk of Surgical Site Infections
in Pediatric Clean Orthopedic Surgery
Jeffrey J. Cies,1,2 Shannon Chan,2 Jobayer Hossain,2 B. Randall Brenn,2,3 and M. Cecilia Di Pentima4
Abstract
Objective: To evaluate body mass index (BMI) and antimicrobial dose as risk factors for surgical site infections in
pediatric patients.
Patients and Methods: Children between 2 and 19 years of age undergoing clean orthopedic procedures and
receiving at least one dose of perioperative antibiotics (cefazolin, vancomycin, or clindamycin) were studied. The
retrospective case-controlled study was conducted at the Alfred I. duPont Hospital for Children, a 180-bed
tertiary-care academic pediatric hospital in Wilmington, DE. Data were collected from January 1, 2002, to
December 31, 2005.
Results: Underweight children had a higher risk for SSIs than overweight and normal-weight children.
American Society of Anesthesiologists classes II and greater were associated with a greater risk of SSI. Longer
procedures were also associated with a higher risk of SSI, specifically, duration of surgery > 2 h. Children
weighing ‡ 70 kg who received a standard dose of cefazolin (maximum of 1 g) had a higher risk of SSI caused by
methicillin-sensitive Staphylococcus aureus (MSSA).
Conclusions: Being underweight and undergoing an operation lasting > 2 h created significant risks for SSI.
Children weighing ‡ 70 kg receiving a standard 1-g dose of cefazolin had a greater risk of MSSA SSIs than
children weighing < 70 kg who received an appropriate weight-based dose of this antibiotic.
The U.S. Centers for Disease Control and Prevention(CDC) estimates that surgical site infections (SSIs) are the
second most common type of hospital-acquired infection,
accounting for 22% of all such infections. Surgical site infec-
tions increase the hospital length of stay significantly and
entail a total increase in cost ranging from $10,443 to $25,546
[1–3]. Currently, limited information exists regarding risk
factors for or causes of SSIs in the pediatric population.
Poor nutritional status is associated with more SSIs in the
literature [4–7]. Obesity is a well-known risk factor for SSI in
the adult population [4,5,8,9]. Studies suggest that current
antibiotic dosing for surgical prophylaxis in obese adult
patients may fail to provide adequate perioperative prophy-
laxis [10–12]. Furthermore, data from adults demonstrate that
the volume of distribution and total body clearance of drugs is
altered in obese patients. Factors affecting tissue concentra-
tions of drug and the volume of distribution include body
composition, regional blood flow, and the affinity of the
therapeutic agent for plasma proteins and the selected tissue
compartment [11,12]. Blood flow per gram of fat is reduced
greatly in morbidly obese patients compared with their
moderately overweight or lean counterparts [13]. In addition,
pediatric patients have faster metabolism and elimination of
drugs than adults; therefore, obese pediatric patients could
have a higher risk of SSI, as suggested by a recent case-control
study [14]. In the studies byMalone et al. [6] and Pessaux et al.
[7], both underweight and malnourishment (defined as >10%
weight loss in the six months prior to surgery) were shown to
be risk factors for SSIs in the adult population. However, data
evaluating body mass index (BMI) as a risk factor for SSI are
lacking.
The primary objective of this study was to determine
whether BMI is a risk factor for SSIs in pediatric patients un-
dergoing clean orthopedic surgical procedures. A secondary
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objective was to determine the impact of weight-based dosing
of perioperative antibiotics on the risk of SSIs. To the best of
our knowledge, this is the first study specifically evaluating
the association between BMI and antimicrobial dose and the
risk of SSIs in pediatric patients undergoing clean orthopedic
procedures.
Patients and Methods
Study design and patient population
This study was approved by the Nemours Institutional
Review Board. It was a retrospective case-control study con-
ducted at the Alfred I. duPont Hospital for Children, a 180-
bed tertiary-care academic pediatric hospital in Wilmington,
DE. Data were collected for January 1, 2002, to December 31,
2005. Patients between 2 and 19 years of age who underwent
an elective, clean orthopedic procedure and received at least
one dose of a peri-operative antibiotic (cefazolin, vancomycin,
or clindamycin) were included. Surgical site infection was
defined according to the Infectious Diseases Society of
America (IDSA) and Surgical Infection Prevention Project
(SIP) definitions [15,16]. Patients who did not have instru-
mentation placed during their procedure had to have an in-
fection develop within 30 d of the procedure. If patients did
have instrumentation placed, the infection had to develop
within one year of the date of surgery [15,16].We attempted to
match one case to two controls (i.e., one infected patient to two
non-infected patients) based on surgical site and procedure
and age. There were 105 cases and 212 controls. Subjects were
categorized into three BMI groups based on the CDC defini-
tion: Healthy weight (BMI fifth through 84th percentile for
age and gender), underweight (BMI less than fifth percentile
for age and gender), and overweight (BMI ‡ 85th percentile
for age and gender). Obesity was defined according to the
CDC guidelines [17]. A repeat dose was defined as an addi-
tional perioperative antibiotic administered during the sur-
gical procedure. The American Society of Anesthesiologists
(ASA) classification system grade was collected for each pa-
tient. The ASA classification is used to stratify the severity of a
patient’s underlying disease and potential for suffering com-
plications from general anesthesia. The classification is as
follows:
Class I: Normal healthy patient;
Class II: A patient with mild systemic disease and no
functional limitations;
Class III: A patient with severe systemic disease and
definite functional impairment;
Class IV: A patient with severe systemic disease that is a
constant threat to life;
Class V: An unstable moribund patient not expected to
survive 24 h with or without the operation;
Class VI: A brain-dead patient whose organs are to be
removed for donation.
Data collection
Patients who underwent clean orthopedic surgical proce-
dures and developed SSI were retrieved from the A. I. duPont
Hospital Infection Control database. A diagnosis of SSI for
each patient was performed by the orthopedic surgeon and
reported monthly to Infection Control. Medical records were
reviewed for each patient. The data collected included height,
weight, age, gender, ethnicity, ASA class, duration of surgery
(<2 or ‡2h), type of surgical procedure, timing of antibiotic
dose before the first incision, doses of perioperative antibiotic
received, and microbiology findings. Surgical procedures were
categorized into the following types: Spine, upper extremity,
lower extremity, hip, and multiple sites. The timing of first an-
tibiotic dose was categorized into the following: At the time of
incision, 0–30 min, 30–60 min, and >60 min after the first inci-
sion. Doses of antibiotics were classified as therapeutic or
subtherapeutic (defined as 10% below the therapeutic dose)
based on the target range of 20–30mg/kg for cefazolin to a
maximum standard dose of 1g, 7.5–10mg/kg for clindamycin
to a maximum standard dose of 600mg, or 10–15mg/kg for
vancomycin to a maximum standard dose of 1g [15,16].
Statistical analyses
The study variables were presented by main predictor BMI
status and response variable infection status (case and con-
trol). Categorical variables were described using frequency
and percentages, whereas continuous variables were sum-
marized using mean, standard deviation, minimum, and
maximum. A Pearson w2 statistic and two-sample t-test for
categorical and numerical variables, respectively, were used
to examine the balance of distribution of the study charac-
teristics among the BMI groups and infection status. A simple
binary logistic regression was used to detect the association of
an SSI with BMI and other study variables. The odds ratios
(ORs), alongwith 95% confidence intervals (CIs) and p values,
were provided to compare the prevalence of SSI for different
groups of predictors. In addition, a multiple logistic regres-
sion model was used to adjust simultaneously for the effect of
the potential confounding variables on the association be-
tween SSI and BMI. To be included in the adjusted model, a
variable must have been either clinically or statistically
significant at p < 0.1. Subanalyses were attempted to deter-
mine the impact of a weight-based dose of cefazolin on the
methicillin-sensitive Staphylococcus aureus (MSSA) infection
status. A simple logistic regression analysis was performed to
compare the SSI rates of individualswhoweighed ‡ 70 kg and
those who weighed < 70 kg. Another simple logistic regres-
sion was performed to compare the odds of developing an SSI
caused by MSSA among any kind of infection between indi-
viduals ‡ 70 kg and < 70 kg. All analyses were two-tailed at
the p < 0.05 significance level. All analyses were performed
using the statistical package SPSS version 17.0 (Chicago, IL).
Results
Table 1 displays the study variables stratified according to
BMI. The difference in the distribution of gender, age, ASA
class, and surgical site among the three BMI groups was sig-
nificant (p < 0.05). There was no difference in the distribution
of ethnicity or the duration of surgery. The majority of
patients with SSI had positive surgical site cultures (93%;
98/105) at the time of diagnosis. Of these, 28.5% (28) had
polymicrobial growth. S. aureus was recovered in 65% of
patients (69/105) with SSI. Table 2 depicts all isolates recov-
ered from surgical site cultures.
Table 3 shows the association between the risk of devel-
oping an SSI and BMI and the other study variables. Patients
who were classified as underweight had a higher risk of SSI
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than patients classified as of healthyweight (OR 2; 95%CI 1.1-
3.67; p = 0.023). The ASA class was also a risk factor for SSI.
Specifically, both ASA class II–III (OR 2.6; 95% CI 1.2-5.5;
p = 0.014) and ASA class > III (OR 5.7; 95% CI 2.6-12.3;
p < 0.001) were associated with a higher risk of SSIs. The
duration of surgery was associated with the risk of SSI, as
surgery requiring > 2 h increased the risk significantly (OR
2.2; 95%CI 1.3-3.8; p = 0.004). On the other hand, ethnicity and
gender were not associated with the risk of SSI.
The results of the multivariable logistic regression analysis
are shown in Table 4. After adjustment for other variables, the
risk of SSI in patients classified as underweight compared with
the healthy-weight group did not reach statistical significance
(OR 1.695; 95% CI 0.835-3.44; p= 0.144). In our model, an ASA
class of II or III (OR 3.6; 95%CI 1.48-8.87; p= 0.006) and anASA
class > III (OR 7.8; 95% CI 2.97-20.57; p< 0.001) both were de-
termined to be risk factors for SSI. Moreover, the association
between SSIs and duration of surgery > 2h remained signifi-
cant (OR 2.4; 95% CI 1.24-4.85; p= 0.01).
To evaluate our secondary objective, a subanalysis was
performed to determine the impact of the dose of cefazolin on
the rate of SSIs caused byMSSA, stratified according to patient
weight. In our cohort, 200 patients received cefazolin for pe-
rioperative prophylaxis. Of these patients, 161 (80%) weighed
< 70kg. Patients weighing < 70kg received an appropriate
weight-based dose of cefazolin to a maximum of 1 g, and pa-
tients weighing ‡ 70kg received a standard 1-g dose. Of the
200 patients who received cefazolin, 47 (23.5%) developed an
SSI caused by MSSA, and 153 (76.5%) did not develop SSI.
Table 1. Baseline Characteristics of 317 Pediatric Patients Undergoing Clean
Orthopedic Surgical Procedures by Body Mass Index (BMI) Group
BMI group
Variable Healthy weight (%) Underweight (%) Overweight (%) Total patients pa
Male/female 87 (51)/111 (76) 43 (25)/15 (10) 41 (24)/20 (14) 171/146 < 0.001
Ethnicity 0.646
African American 26 (59.1) 9 (20.5) 9 (20.5) 44
Caucasian 160 (64.3) 44 (17.7) 45 (18.1) 249
Other 12 (50) 5 (20.8) 7 (29.2) 24
Age (years) 0.040
N 198 58 61 317
Mean (SD) 12.9 (3.65) 13.6 (3.98) 11.9 (3.78) 12.8 (3.78)
Range 4–19 3–18 3–17 3–19
ASA class < 0.001
I 53 (76.8) 4 (5.8) 12 (17.4) 69
II or III 92 (63.9) 20 (13.9) 32 (22.2) 144
> III 53 (51) 34 (32.7) 17 (16.3) 104
Duration of surgery (h) 0.881
< 2 67 (64.4) 18 (17.3) 19 (18.3) 104
‡ 2 131 (61.5) 40 (18.8) 42 (19.7) 213
Surgical site 0.001
Spine 87 (59.2) 36 (24.5) 24 (16.3) 147
Upper extremity 13 (56.5) 5 (21.7) 5 (21.7) 23
Lower extremity 53 (65.4) 3 (3.7) 25 (30.9) 81
Hip 30 (65.2) 12 (26.1) 4 (8.7) 46
Multiple sites 15 (75) 2 (10) 3 (15) 20
Timing of preoperative antibiotic (min) 0.306
< 0 30 (71.4) 6 (14.3) 6 (14.3) 42
0–30 123 (64.1) 30 (15.6) 39 (20.3) 192
30–60 32 (55.2) 14 (24.1) 12 (20.7) 58
> 60 13 (52) 8 (32) 4 (16) 25
Repeat dose 0.013
No 178 (60.3) 58 (19.7) 59 (20) 295
Yes 20 (90.9) 0 (0) 2 (9.1) 22
aP value is from either w2 statistic or one-way analysis of variance.
ASA=American Society of Anesthesiologists; SD = standard deviation.
Table 2. Bacteria Recovered from 98 Pediatric
Patients with Surgical Site Infection (SSI)a
Microorganism Number of isolates (%)
Staphylococcus aureus
Methicillin sensitive 47 (33)
Methicillin resistant 22 (16)
Coagulase-negative staphylococci 18 (13)
Pseudomonas aeruginosa 16 (11.3)
Escherichia coli 8 (5.7)
Enterococcus faecalis 11 (7.8)
Proteus mirabilis 8 (5.7)
Acinetobacter baumannii 5 (3.5)
Enterobacter cloacae 6 (4)
Total 141
aOf the 105 SSI cases, 98 patients had microbiology data
supporting the infection. Of these patients, 28 had polymicrobial
infections.
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Those patients who weighed ‡ 70kg had a statistically signif-
icant increase in the risk of MSSA SSI compared with patients
who weighed < 70kg, 35.9% (14/39) vs. 20.5% (33/161), re-
spectively (OR 2.17; 95% CI 1.02-4.64; p= 0.045).
Discussion
There are data demonstrating alterations in pharmacoki-
netics and pharmacodynamics of drugs in obese adults
comparedwith non-obese patients. These alterations are a risk
factor for SSIs, as aremalnourishment and being underweight
[6,7,10–13]. Taking into consideration some additional factors
specific to pediatric patients, such as their greater renal
elimination, it was hypothesized that in pediatric patients, the
incidence of SSIs could differ with BMI status [14]. To the
authors’ knowledge, there is only a single study evaluating
the risk factors for SSI in a pediatric population undergoing
clean orthopedic surgical procedures [14].
In our cohort, being overweight was not a risk factor for
SSI. Nevertheless, children and adolescents weighing ‡ 70 kg,
regardless of BMI status, did have a higher risk of SSI
compared with children and adolescents weighing < 70 kg
receiving an appropriate weight-adjusted dose of cefazolin to
a maximum of 1 g. The organism most often implicated in the
SSIs in children and adolescents who weighed ‡ 70 kg was
Table 3. Baseline Characteristics of 317 Pediatric Patients Undergoing Clean
Orthopedic Surgical Procedures by Infection Status
Infection status (%)
Variable Infected Not infected Total patients Odds ratio (95% CI) pa
Gender
Male 61 (35.7) 110 (64.3) 171 Reference
Female 44 (30.1) 102 (69.9) 146 0.807 (0.514-1.270) 0.297
Ethnicity
African American 20 (45.5) 24 (54.5) 44 Reference
Caucasian 78 (31.3) 171 (68.7) 249 0.547 (0.285-1.050) 0.070
Other 7 (29.2) 17 (70.8) 24 0.494 (0.171-1.428) 0.193
Age (years) 0.989 (0.930-1.052) 0.729
N 105 212 317
Mean (SD) 12.7 (3.86) 12.9 (3.75) 12.8 (3.78)
Range 3–18 3–19 3–19
BMI group
Healthy weight 57 (28.8) 141 (71.2) 198 Reference
Underweight 26 (44.8) 32 (55.2) 58 2.010 (1.101-3.670) 0.023
Overweight 22 (36.1) 39 (63.9) 61 1.395 (0.761-2.559) 0.282
ASA class
I 10 (14.5) 59 (85.5) 69 Reference
II or III 44 (30.6) 100 (69.4) 144 2.596 (1.216-5.541) 0.014
> III 51 (49) 53 (51) 104 5.677 (2.622-12.295) < 0.001
Duration of surgery (h)
< 2 23 (22.1) 81 (77.9) 104 Reference
‡ 2 h 82 (38.5) 131 (61.5) 213 2.204 (1.289-3.779) 0.004
Timing of preoperative antibiotic (min)
< 0 12 (28.6) 30 (71.4) 42 Reference
0–30 66 (34.4) 126 (65.6) 192 1.310 (0.629-2.725) 0.471
30–60 18 (31) 40 (69) 58 1.125 (0.471-2.686) 0.79
> 60 9 (36) 16 (64) 25 1.406 (0.489-4.043) 0.527
aP value is from either w2 statistic or one-way analysis of variance.
BMI= body mass index; SD= standard deviation.
Table 4. Body Mass Index (BMI) Does Not
Predict a Higher Risk of Surgical Infection
after Clean Orthopedic Surgical Procedures
in Pediatric Patients
Variable Odds ratio (95% CI) p
BMI group
Healthy weight Reference (1.0) –
Underweight 1.695 (0.835-3.440) 0.144
Overweight 1.049 (0.507-2.170) 0.898
ASA class
I Reference (1.0) –
II or III 3.626 (1.483-8.869) 0.006
> III 7.810 (2.966-20.566) < 0.001
Duration of surgery (h)
< 2 Reference (1.0) –
‡ 2 2.447 (1.236-4.846) 0.010
Ethnicity
African American Reference (1.0) –
Caucasian 0.506 (0.156-1.634) 0.255
Other 0.725 (0.349-1.508) 0.390
Multivariable logistic regression analysis to determine the effect of
BMI after adjustment of the effect of covariates.
CI= confidence interval.
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MSSA. Guidelines published by the American Society of
Health-System Pharmacists recommend 1 g of cefazolin for all
adult orthopedic surgical procedures, including those in-
volving implantation of foreign materials [16]. Guidelines for
pediatric patients recommend 20–30mg/kg/dose [16]. At
Nemours, surgical prophylaxis guidelines have followed
these recommendations, and in most cases, cefazolin is cap-
ped at 1 g/dose. A recent advisory statement from the
National Surgical Infection Prevention Project recommends a
maximum single dose of 2 g of cefazolin for patients weighing
at least 80 kg [15]. This recommendation was based on a
higher risk of SSI among adult patients weighing > 80 kg who
underwent gastroplasty and received a 1-g dose of cefazolin
in comparison with patients receiving twice that dose. Simi-
larly, our cohort of pediatric patients who weighed ‡ 70 kg
had a higher risk of SSI when receiving a 1-g dose of cefazolin
as preoperative surgical prophylaxis for clean orthopedic
surgical procedures. Therefore, caution is needed when set-
ting institution-specific maximum doses for perioperative
prophylaxis with cefazolin, and the 20–30mg/kg/dose rec-
ommendation should be followed to a maximum of 2 g/dose.
In our cohort, underweight children and adolescents with a
BMI less than the fifth percentile had a greater risk of SSI by
univariable analysis, which is consistent with published data
in adults [6,7]. One hypothesis to explain this finding is that
children who are underweight, according to their BMI, often
are malnourished. Additionally, underweight children may
not have the immunologic reserve to defend against an
infection because of their poor nutritional status, as poor nu-
tritional status has been suggested to contribute to decreased
lymphocyte function [18,19]. Furthermore, good nutritional
status is crucial for wound healing, which could contribute to
this association and has been demonstrated in other studies
[20,21]. However, in multivariable analysis, this finding was
not found to reach statistical significance.
Linam et al., in a retrospective analysis of children under-
going posterior spinal fusion, recently reported that obese
children had a higher rate of SSI [14].We did not find a greater
rate of SSI in overweight patients. However, our population
was not limited to patients undergoing posterior spinal
fusion. In the study by Linam et al., clindamycin was the peri-
operative antibiotic of choice in 11% of patients, whereas in
our study, the rate of clindamycin use was much lower, at
approximately 1%. Our findings support a higher risk of
MSSA SSIs in patients receiving a standard 1-g dose of cefa-
zolin in patients who weigh ‡ 70 kg. We did not perform a
separate analysis for overweight patients who developed an
MSSA SSI. However, one possible explanation for the differ-
ence in the rate of SSIs in the overweight patients reviewed in
the earlier and our cohort is the choice of perioperative anti-
biotic. Clindamycin and cefazolin have different mechanisms
of action and spectra of activity, and the patients in the study
by Linam et al. had a higher rate of gram-negative SSIs than
did our cohort.
The ASA classification is used to assess a patient’s physical
state prior to selecting anesthesia for surgery, of which nu-
tritional status may be a component. By definition, having a
BMI ‡ 85th percentile for age and gender requires, at a min-
imum, an ASA classification of III. Considering that every
overweight patient has an ASA classification of at least III,
it was surprising that an ASA classification of ‡ III was an
independent risk factor for SSI in both univariable and
multivariable analysis, yet overweight status according to
BMIwas not a risk factor in our analysis; only an underweight
BMI was a risk factor. The ASA classification system is not
based solely on objective criteria, so there is the potential for
misclassifying patients and differences in classification status
depending on the person conducting the evaluation. In our
study, an ASA classification of ‡ III was one of the risk factors
that maintained statistical significance through univariable
and multivariable logistic regression analysis.
Undergoing surgery with a duration of > 2 h was a risk
factor for SSI in both univariable and multivariable analysis.
There are many reasons this could be the case. First, opera-
tions that last > 2 h usually have a greater degree of com-
plexity. With a higher degree of complexity come a larger
number of manipulations and a larger number of areas in-
volved and the potential for injuring/infecting an area in-
volved in the surgery. Second, the amount of blood loss that is
likely to occur with longer operations is greater, and with any
blood loss, there is the potential for lower serum concentra-
tions of the perioperative antimicrobial agent. Having an
appropriate serum concentration of the drug is crucial to en-
sure an appropriate concentration at the site of the potential
infection. Furthermore, in longer operations, the risk of tissue
hypoxemia and hypotension increases. Tissue hypoxia can
occur as a result of reduced perfusion of the area of interest.
One hallmark of successful antimicrobial prophylaxis is de-
livery of the drug to the area of increased infection sus-
ceptibility at an appropriate concentration. With reduced
perfusion of the area of concern, there is a reduction in the
amount of the antimicrobial agent reaching that area. Speci-
fically, for cefazolin, the primary mechanism of efficacy
correlates with the concept of time-dependent killing. With
time-dependent killing, there needs to be a serum concen-
tration at the site of the infection or area of increased risk that
is above the minimum inhibitory concentration (MIC) for as
long as possible to ensure efficacy. With tissue hypoxia and
reduced perfusion, there is less blood with an appropriate
antimicrobial drug concentration, which could contribute to
the higher risk of SSIs when the duration of surgery is > 2 h.
Our results support an association between being under-
weight for age and gender, an ASA status ‡ II, and surgery
lasting > 2 h and a greater risk of SSI. These results are similar
to those of a recent retrospective analysis in children under-
going posterior spinal fusion [14]. Furthermore, our study
supports using a higher dose of cefazolin in children and
adolescents weighing ‡ 70 kg, regardless of BMI status, which
is similar to the recent recommendation in adults to use 2 g of
cefazolin for patients ‡ 80 kg [15].
Conclusions
Our study highlights the importance of optimizing antimi-
crobial dosing in children and adolescents ‡70kg, especially
when using cefazolin, the drug of choice for clean orthopedic
surgical procedures. Additionally, our cohort suggests being
underweight, surgery duration ‡2h, and higher ASA class are
risk factors for SSI after clean orthopedic surgery.
Data presented here were collected as part of a single-
center, retrospective study and have all the attendant limita-
tions: Causation cannot be demonstrated, and the influence of
factors not reviewed cannot be excluded. Furthermore, our
results could be explained by sampling bias. However, this
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study represents the first evaluation specifically of BMI status
and antimicrobial dose in pediatric patients undergoing clean
orthopedic surgery.
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